Mounjaro Vs Saxen da is a basic comparison of the two highly potent diabetes and weight loss drugs.

Mounjaro is a novel drug and innovation in the field of Diabetes Mellitus. It is FDA licensed drug containing dual GIP (glucose-dependent insulinotropic peptide) as well as GLP-1 analog (Glucagon-like peptide), known as Tirzepatide.

It was seen that GIP alone does not have a significant benefit on glycemic control. However, when used in combination with GLP-1 analog, a marvelous synergistic effect was seen and much better glycemic control was observed.

Hence the name Twincretin was used for this combination. Twincretin, as the name suggests, is a combination of two incretins, GLP-1 and GIP.

Whereas Saxen da contains Liraglutide, a GLP-1 analog. It has been approved by the FDA primarily for the treatment of obesity, weight loss, and dyslipidemia.

Saxen da is basically a high-dose Liraglutide while Victoza is a low-dose Liraglutide. Victoza is approved for the treatment of Diabetes only.

Mounjaro Vs Saxen da

Saxen da and Mounjaro are two potent diabetes and weight loss drugs. These drugs have not been compared in a head-to-head comparative trial.

Following are some of the similarities and differences between the two drugs:

Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects.
 

Wegovy should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists, or other products intended for weight loss, including prescription drugs, over-the-counter drugs, or herbal products. Wegovy has not been studied in patients with a history of pancreatitis.

Wegovys safety and efficacy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials (including 16 weeks of dose increases) and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Wegovy either continued with the treatment or switched to a placebo. More than 2,600 patients received Wegovy for up to 68 weeks in these four studies and more than 1,500 patients received placebo.

The largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the trial was 46 years and 74% of patients were female. The average body weight was 231 pounds (105 kg) and average BMI was 38 kg/m2. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years and 51% were female. The average body weight was 220 pounds (100 kg) and average BMI was 36 kg/m2. In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received placebo.

The most common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection) and gastroesophageal reflux disease (a type of digestive disorder).

The prescribing information for Wegovy contains a boxed warning to inform healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).